Sixty-four dogs were placed on normothermic total cardiopulmonary bypass, and global
ischemia was induced for 1 hour during which continuous infusions (240 ml per hour)(N …

This report summarizes five years of laboratory investigations and the initial six-month
clinical experience with a calcium antagonist, nifedipine, added to a cold hyperkalcmic …

This report summarizes studies that provided a basis for a randomized clinical trial of
nifedipine in cold hyperkalemic cardioplegic solution. Data from normothermic, isolated …

Thirty dogs were studied acutely on cardiopulmonary bypass in four groups. Hearts in
Groups IC (standard cardioplegia, n= 5) and 2C (n= 10) were subjected to periods of global …

Nifedipine, a slow-channel calcium blocker, is thought to provide useful myocardial
protection during prolonged total ischemia and reperfusion. An isolated, isovolumic, feline …

The effectiveness of the calcium antagonist nifedipine in preserving postischemic
myocardial function and structural integrity was experimentally demonstrated in isolated …

This study tests the hypothesis that the efficacy of hypothermia as a cardiacprotective agent
can be increased by adding the slow channel-blocking agent, nifedipine. Isolated …

This study tests the hypothesis that the efficacy of cardioplegic solution depends upon its
chemical constituents rather than on its temperature alone. A standard preparation of right …

The cardioprotective effect of the addition of the slow calcium-channel blocker nifedipine to
cardioplegic solution was tested in two double-blind placebo controlled randomized studies …

A clinical trial of nifedipine, a calcium antagonist, in cardioplegic solution was performed
based on previous laboratory data demonstrating improved postischemic performance in …